Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia

Background: Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component). So far, different effects on both BDNF and...

Full description

Bibliographic Details
Main Authors:	Rong-Qin Wu, Chong-Guang Lin, Wei Zhang, Xiao-Dong Lin, Xing-Shi Chen, Ce Chen, Li-Jun Zhang, Zi-Ye Huang, Guang-Dong Chen, Da-Li Xu, Zhi-Guang Lin, Ming-Dao Zhang
Format:	Article
Language:	English
Published:	Wolters Kluwer 2018-01-01
Series:	Chinese Medical Journal
Subjects:	Brain-Derived Neurotrophic Factor; Cognitive Function; Event-Related Potentials; N400; Schizophrenia
Online Access:	http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=19;spage=2297;epage=2301;aulast=Wu

Similar Items

Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia
by: Xiang-Dong Du, et al.
Published: (2015-01-01)

Effects of Repetitive Transcranial Magnetic Stimulation Treatment on Event-Related Potentials in Schizophrenia
by: Xiao-Dong Lin, et al.
Published: (2018-01-01)

Association of serum brain‐derived neurotrophic factor level and early response to antipsychotic drug in first‐episode patients with schizophrenia
by: Tong Zhao, et al.
Published: (2024-03-01)

Contextual impairments in schizophrenia and the FN400
by: Lucia eAmoruso, et al.
Published: (2012-07-01)

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia
by: Yuxuan Wu, et al.
Published: (2022-06-01)

FEATURES OF LIPID PEROXIDATION AND NEUROTROPHIC REGULATION IN PATIENTS SUFFERING FROM PARANOID SCHIZOPHRENIA
by: E.V. Kolesnichenko, et al.
Published: (2008-09-01)

About the nature of contextual impairments revealed by FN400 abnormalities in schizophrenia
by: Fabrice eGuillaume, et al.
Published: (2013-03-01)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
by: Zhao M, et al.
Published: (2023-04-01)

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction
by: Xiaowei Tang, et al.
Published: (2019-08-01)

Diagnostic accuracy of Brain-derived neurotrophic factor and nitric oxide in patients with schizophrenia: A pilot study
by: Đorđević Vladimir V., et al.
Published: (2016-01-01)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
by: Chen Lin, et al.
Published: (2021-11-01)

Drug utilization of paliperidone in adolescent schizophrenia patients: A retrospective cohort study in China
by: S. Dong, et al.
Published: (2021-04-01)

Research on 400 Gbit/s FR4 Optical Transceiver Module
by: Kun DENG, et al.
Published: (2021-06-01)

Brain-derived neurotrophic factor (BDNF) in schizophrenia research: a quantitative review and future directions
by: Rozaziana Ahmad, et al.
Published: (2023-03-01)

Brain-derived neurotrophic factor and mental disorders
by: Chin-Chuen Lin, et al.
Published: (2020-04-01)

The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients
by: Kiyokazu Atake, et al.
Published: (2018-05-01)

Effects of isolation rearing and early antipsychotic intervention on oxidative stress-induced apoptosis and brain-derived neurotrophic factor in hippocampus in a rat model of schizophrenia
by: Szu-Nian Yang, et al.
Published: (2017-01-01)

A longitudinal study of serum brain-derived neurotrophic factor levels in first-episode schizophrenia
by: Yee, Jie Yin, et al.
Published: (2021)

IBM AS/400 : a business perspective /
by: 352693 Hoskins, Jim
Published: (1989)

AS/400 information engineering /
by: 259982 Porter, John
Published: (c199)

Relevance of Brain-derived Neurotrophic Factor Levels in Schizophrenia: A Systematic Review and Meta-Analysis
by: Franco F Orsucci, et al.
Published: (2015-11-01)

Neurotrophic basis to the pathogenesis of depression and phytotherapy
by: Huiqin Wang, et al.
Published: (2023-04-01)

The Role of Brain-Derived Neurotrophic Factor (BDNF) in Diagnosis and Treatment of Epilepsy, Depression, Schizophrenia, Anorexia Nervosa and Alzheimer’s Disease as Highly Drug-Resistant Diseases: A Narrative Review
by: Aleksandra Gliwińska, et al.
Published: (2023-01-01)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
by: Charmi Patel, MPH, RN, et al.
Published: (2020-01-01)

Crocin alleviates schizophrenia-like symptoms in rats by upregulating silent information regulator-1 and brain derived neurotrophic factor
by: Xi-juan Sun, et al.
Published: (2020-11-01)

The Influence of Electroconvulsive Therapy (ECT) on Brain-Derived Neurotrophic Factor (BDNF) Plasma Level in Patients with Schizophrenia—A Systematic Review and Meta-Analysis
by: Anna Maria Szota, et al.
Published: (2023-09-01)

Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
by: Alexander Hodkinson, et al.
Published: (2021-08-01)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function
by: Ying Yang, et al.

Sodium Valproate as an Adjunctive to Risperidone in Treatment of Schizophrenia
by: V Omrani Fard, et al.
Published: (2007-01-01)

AS/400 system management [jurnal elektronik]

The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia
by: Yichen Li, et al.
Published: (2020-09-01)

EXPERIMENTAL MODEL OF SCHIZOPHRENIA AND MORPHOLOGICAL CHANGES IN BRAIN
by: L. Grozlekova, et al.
Published: (2019-11-01)

Relationships between brain-derived neurotrophic factor, clinical symptoms and decision-making in chronic schizophrenia: data from the Iowa Gambling Task
by: Hikaru eHori, et al.
Published: (2014-12-01)

Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naive first-episode schizophrenia with risperidone monotherapy
by: Xiaofen Zong, et al.
Published: (2023-03-01)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023-08-01)

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
by: Yuying Qiu, et al.
Published: (2023-04-01)

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study
by: Xiaoe Lang, et al.
Published: (2023-07-01)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
by: Schooler Nina, et al.
Published: (2011-02-01)

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia
by: Betul Aslan Turkmen, et al.
Published: (2021-11-01)

Differences of 2.2% and 2.8% Dehydration Effects on 400 Meter Running Performance
by: Isti Dwi Puspita Wati
Published: (2021-09-01)